Could a vaccine combo free people with HIV from daily pills?

NCT ID NCT06071767

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special T-cell vaccine, combined with an immune-boosting drug (vesatolimod) and two powerful antibodies, can help people with HIV control the virus without needing daily antiretroviral therapy. The trial involves 36 adults who started HIV treatment soon after infection and have been on stable therapy for at least a year. Participants will receive the vaccine regimen or a placebo, then temporarily stop their regular HIV meds to see if the new approach keeps the virus in check.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: T-cell vaccine (ChAdOx1-MVA/HIVconsvX), vesatolimod, and broadly neutralizing antibodies (GS-5423, GS-2872)
What this could lead to: If successful, this could point toward a way for people with HIV to stop daily antiretroviral therapy while keeping the virus under control.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply broadly. The combination regimen is complex and may cause side effects or fail to control the virus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Chapel Hill CRS
RECRUITING

Chapel Hill, North Carolina, 27599, United States
Columbia Physicians & Surgeons CRS
RECRUITING

New York, New York, 10032, United States
Houston AIDS Research Team CRS
RECRUITING

Houston, Texas, 77004, United States
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
NOT_YET_RECRUITING

Rio de Janeiro, Brazil
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS
RECRUITING

Porto Alegre, Rio Grande do Sul, 91350-180, Brazil
Massachusetts General Hospital CRS (MGH CRS)
NOT_YET_RECRUITING

Boston, Massachusetts, 02114, United States
Northwestern University CRS
RECRUITING

Chicago, Illinois, 60611, United States
Ohio State University CRS
RECRUITING

Columbus, Ohio, 43210, United States
Penn Therapeutics CRS
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Ponce de Leon Center CRS
RECRUITING

Atlanta, Georgia, 30308, United States
University of California, San Diego AntiViral Research Center CRS
RECRUITING

San Diego, California, 92103, United States
Washington University Therapeutics CRS
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.